SeekingAlpha  May 23  Comment 
FiercePharma  May 23  Comment 
AstraZeneca finally has some cardiovascular outcomes data it can tout in favor of one of its top diabetes contenders, the long-acting GLP-1 drug Bydureon. But its new results still don’t measure up to data posted by its competitors.
FiercePharma  May 22  Comment 
Novo Nordisk, facing more pressure than ever in the U.S., is revving up its Latin American plans for the obesity drug Saxenda, which shows particular promise in Mexico.
FiercePharma  May 22  Comment 
As a variety of states weigh measures targeting pharmaceutical pricing, Nevada’s Senate has passed a tough new bill that would publicly spotlight insulin makers' price hikes and profits.
Motley Fool  May 19  Comment 
Looking for obesity-drug stocks to buy? Check out the biggest and best: Eisai, Novo Nordisk, and Roche.
MedPage Today  May 12  Comment 
(MedPage Today) -- News and commentary from the endocrinology world
Motley Fool  May 4  Comment 
The diabetes specialist hits lowered expectations in the first quarter.
MedPage Today  May 4  Comment 
(MedPage Today) -- De novo nephritis numbers were miniscule in prospective study

You may also be interested in articles related to Novo Nordisk A/S (NVO):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki